Drug intelligence / Profile preview

Suting Wan

Development stage: Unknown
Lead developer: Children's Hospital, Zhejiang University School of Medicine
Administration: Oral

Overview

Suting Wan is a Traditional Chinese Medicine (TCM) formulation primarily used in pediatric respiratory care for the treatment of bronchial asthma and cough, particularly during the acute onset stage characterized by heat-induced syndromes. It is typically composed of herbal ingredients such as *Fructus Perillae* (Su Zi) and *Semen Lepidii* (Ting Li Zi), which are traditionally used to descend Qi, resolve phlegm, and relieve wheezing. In clinical practice, it is frequently used in combination with other classic formulas like Maxing Shigan Tang to manage pediatric asthma symptoms. The formula is currently being evaluated in multicenter clinical trials in China to establish its efficacy and safety in children aged 5–12 years.

Other names: Su Ting Wan苏葶丸

Beyond the preview

Go deeper on Suting Wan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suting Wan.

Explore the full profile